1. Background {#sec149559}
=============

The extended-spectrum β-lactamases (ESBLs) including CTX-M-type and PER enzymes have increased among Enterobacteriaceae in many parts of the world ([@A22260R1]). Until now 90 different CTX-M β-lactamases have been described and divided into five phylogenetic groups ([@A22260R2], [@A22260R3]). CTX-M type β-lactamases re classified under amber class A which induce high level resistance to ceftazidime, cefotaxime and aztreonam ([@A22260R4]). PER enzymes, as a class A extended-spectrum beta-lactamase also confer resistance to oxyimino beta-lactams ([@A22260R5]).

Due to extensive use of β-lactam antibiotic over the last several decades in the healthcare centers, various β-lactamases have emerged ([@A22260R5]). Extended spectrum β-lactamases (ESBLs) are the enzymes produced by gram-negative pathogens hydrolyze β-lactam antibiotics containing an oxyimino group (third generation cephalosporins and aztreonam) and are inhibited by β-lactamase inhibitors such as clavulanic acid, sulbactam and tazobactam ([@A22260R6], [@A22260R7]). ESBLs are prevalent in different parts of the world and are mainly identified among Enterobacteriaceae family such as *Klebsiella pneumoniae* strains ([@A22260R8], [@A22260R9]). Infections due to these ESBL-positive *Klebsiella* isolates cause increased morbidity and mortality ([@A22260R10]). CTX-M-producing *Klebsiella pneumoniae* are increasingly involved in infections, especially among hospitalized patients. Furthermore, these bacteria seem to have been imported from the community into the clinical settings ([@A22260R11]). The prevalence of ESBL producing *K. pneumoniae* varies in different countries, although CTX-M type β-lactamase enzymes are the predominant ESBLs in the most parts of the world ([@A22260R12]-[@A22260R16]). The prevalence of ESBL producing *K. pneumoniae* in Iran is reported to range from 19.6 to 75% ([@A22260R17]-[@A22260R21]). In Kashan, few studies have been performed to determine the prevalence of ESBL genes among *K. pneumonia* isolates especially those of *bla*~*PER*~ and *bla*~*CTX-M*~.

2. Objectives {#sec149560}
=============

The current study aimed to determine the prevalence of *bla*~*PER*~ and *bla*~*CTX-M*~ genes among ESBL producing *Klebsiella* strains which can provide useful epidemiological information that might aid the management of antimicrobial therapies.

3. Patients and Methods {#sec149566}
=======================

3.1. Bacterial Isolates {#sec149561}
-----------------------

One hundred *Klebsiella* isolates were collected from clinical specimens of hospitalized patients at Shahid-Beheshti hospital in Kashan from December 2012 to November 2013. The species were isolated from patients of both genders (64% female, 36% male). The *Klebsiella* strains were identified by standard microbiological tests ([@A22260R22]).

3.2. Antibiotic Susceptibility Test {#sec149562}
-----------------------------------

The isolates were tested for antimicrobial susceptibility pattern by the disk diffusion method according to the CLSI guidelines ([@A22260R23]). Antimicrobial susceptibility testing was performed on Mueller-Hinton agar. The following antibiotic disks were used: ampicillin (30 Μg), aztreonam (30 Μg), amoxicillin/clavulanic acid (20 Μg), cephalothin (30 Μg), cefixime (30 Μg), nalidixicacid (30 Μg), trimethoprim-sulfamethoxazole (25 Μg), imipenem (10 Μg), ceftazidime (30 Μg), cefoxitin (30 Μg), cefteriaxon (30 Μg), gentamicin (10 Μg), ciprofloxacin (5 Μg) and nitrofurantoin (300 Μg). The antibiotic disks were obtained from MAST company (Mast Companies, UK) and the quality control organism was *Escherichia coli* ATCC 25922.

3.3. ESBL Detection by Double Disk Synergy Test {#sec149563}
-----------------------------------------------

ESBL production of all the 100 *Klebsiella* strains was confirmed by ceftazidime (30 Μg) and cefotaxime (30 Μg) antibiotic disks with and without clavulanic acid (10 Μg), by double disk synergy test (DDST). Briefly, the organisms were swabbed on to Mueller-Hinton agar plates (as performed for disc diffusion), then an amoxicillin-clavulanate disk (20 + 10 Μg) was placed in the center of the plate and ceftizoxime (30 Μg), cefotaxime (30 Μg) and cefteriaxon (30 Μg) discs were placed 15 mm away from the central disk ([@A22260R24], [@A22260R25]). The plates were incubated at 37°C for up to 24 hours. An increase of \> 5 mm inhibition zone for antibiotics around the amoxyclav disk compared to that of the cephalosporin disk alone was considered ESBL production. ESBL producing strain *K. pneumoneae* ATCC 700603 and non-ESBL producing strain *E. coli* ATCC 25922 were used as positive and negative controls respectively ([@A22260R23]).

3.4. Detection of blaCTX-M and blaPER Genes by PCR {#sec149564}
--------------------------------------------------

DNAs of isolates were extracted using boiling method and PCR amplification was carried out using specific primers for *bla*~*CTX-M*~ gene including: 5\'-CGCTTTGCGATGTGCAG-3\', and 5\'-ACCGCGATATCGTTGGT-3\' to amplify a 590 bp fragment and *bla*~*PER*~ gene specific primers including: 5\'-GTTAATTTGGGCTTAGGGCAG-3\', and 5\'-CAGCGCAATCCCCACTGT-3\' to amplify an 855 bp fragment ([@A22260R26]). PCR was performed in 25 ΜL volume reaction mixtures containing 10 pM of each primer, 200 Μm dNTP, 1.5 Μm MgCl~2~, 1.5 ΜL of template DNA and 1 U Taq DNA polymerase in the reaction buffer provided by the manufacturer (CinnaGen, Tehran, Iran). The following thermo-cycling program was carried out for PCR experiments: initial denaturation at 94°C for 5 minutes; 30 cycles of 94°C for 25 seconds, 52°C for 40 seconds and 72°C for 50 seconds; and a final elongation at 72°C for 6 minutes in a thermal cycler (Eppendorf master cycler®, MA). The amplified products were electrophoresed and separated on 2% agarose gel. The gel was visualized by staining with ethidium bromide (0.5 mg/mL) in a dark room for 30 minutes. A 100 base pair ladder was used as molecular weight marker to measure the molecular weight of the amplified products (100 bp DNA ladder, MBI Fermentas). The images of ethidium bromide stained DNA bands were analyzed using a gel documentation system (Biorad, UK).

3.5. DNA Sequencing {#sec149565}
-------------------

The purified PCR products were sequenced using the ABI capillary system (Macrogen Research, Seoul, Korea). Sequences were compared using online BLAST software (http://www.ncbi.nlm. nih.gov/BLAST/).

4. Results {#sec149567}
==========

A total of 100 Klebsiella isolates were obtained from patients at the hospital. They were from urine (75%), sputum (7%), blood (6%) and tracheal aspirate (12%). The mean age of the infected patients was 45 years (aged between 0 - 90 years old) and the median length of hospitalization was seven days. Samples were isolated from patients of both genders (64% female, 36% male) ([Table 1](#tbl38283){ref-type="table"}).

###### Comparison of Demographic and Laboratory Data Among ESBL Positive and ESBL Negative *Klebsiella* Isolates^[a](#fn41279){ref-type="table-fn"}^

  Factors                            ESBL Negative   ESBL Positive   P Value
  ---------------------------------- --------------- --------------- ---------
  **Age, y**                                                         0.306
  ≥ 50                               11 (16.9)       29 (82.9)       
  \< 50                              54 (83.1)       6 (17.1)        
  **Gender**                                                         0.540
  Male                               22 (33.8)       14 (40)         
  Female                             43 (66.2)       21 (60)         
  **Type of admission**                                              0.140
  Hospitalization                    49 (75.4)       27 (77.1)       
  Outpatient                         16 ( 24.6 )     8 (22.9)        
  **Length of hospitalization, y**                                   0.002
  \> 7                               6 (9.2)         6 (17.1)        
  ≤ 7                                59 (90.8)       29 (82.9)       
  **Ward**                                                           0.013
  ICU                                14 (21.5)       17 (48.6)       
  Medical                            8 (12.3)        0               
  Infectious                         28 (43.1)       12 (34.3)       
  Surgery                            0 (0 )          0               
  Obstetrics and gynecology          0 (0 )          0               
  Children                           11 (16.9)       4 (11.4)        
  Emergency                          0               0               
  CCU                                4 (6.2)         2 (5.7)         
  **Sample type**                                                    0.004
  Urine                              46 (70.8)       29 (82.9)       
  Sputum                             7 (10.8)        0               
  Catheters                          0               0               
  Blood                              6 (9.2)         0               
  Wound                              0               0               
  Tracheal aspirate                  6 (9.2)         6 (17.1)        
  **Resistance pattern**                                             0.105
  Drug resistance                    36 (55.4)       0               
  Multi drug resistance              29 (44.6)       35 (100)        

Abbreviation: ESBL, Extended-spectrum β--Lactamase.

^a^Values are expressed as No. (%).

The antibiotic susceptibility profile measured by disk diffusion is shown in [Table 2](#tbl38284){ref-type="table"}. The highest rate of resistance was to ampicillin (92 %) and the lowest to imipenem (7%). The resistance rate among ESBL producing *Klebsiella* isolates was higher than that of non-ESBL producing *Klebsiella* isolates ([Table 3](#tbl38285){ref-type="table"}).

###### The Antibiotic Susceptibility Profile of Klebsiella Isolates Measured by Disk Diffusion Method^[a](#fn41280){ref-type="table-fn"}^

  Antibiotic                        Isolates   
  --------------------------------- ---------- ---------
  **Ampicillin**                    8 (8)      92 (92)
  **Nalidixic acid**                49 (49)    51 (51)
  **Cotrimoxazole**                 75 (75)    25 (25)
  **Ciprofloxacin**                 67 (67)    33 (33)
  **Ceftriaxone**                   65 (65)    35 (35)
  **Aztreonam**                     64 (64)    36 (36)
  **Ceftazidime**                   67 (67)    33 (33)
  **Cephalothin**                   56 (56)    44 (44)
  **Gentamicin**                    80 (80)    20 (20)
  **Nitrofurantoin**                64 (64)    36 (36)
  **Amoxicillin-clavulanic acid**   51 (51)    49 (49)
  **Cefoxitin**                     74 (74)    26 (26)
  **Cefotaxime**                    59 (59)    41 (41)
  **Imipenem**                      93 (93)    7 (7)

^a^Values are expressed as No. (%).

###### The Antibiotic Susceptibility Patterns Among ESBL Producing *Klebsiella* Isolates^[a](#fn41281){ref-type="table-fn"}^

  Antibiotic                        Isolates    
  --------------------------------- ----------- -----------
  **Ampicillin**                    35 (100)    0
  **Nalidixic acid**                27 (77.1)   8 (22.9)
  **Cotrimoxazole**                 24 (68.6)   11 (31.4)
  **Ciprofloxacin**                 9 (25.7)    26 (74.3)
  **Ceftriaxone**                   25 (71.4)   10 (28.6)
  **Aztronam**                      30 (85.7)   5 (14.3)
  **Ceftazidime**                   26 (74.3)   9 (25.7)
  **Cephalothin**                   18 (51.4)   44 (48.6)
  **Gentamicin**                    9 (25.7)    26 (74.3)
  **Nitrofurantoin**                10 (28.6)   25 (71.4)
  **Amoxicillin-clavulanic acid**   31 (88.5)   4 (11.5)
  **Cefoxitin**                     17 (48.6)   18 (51.4)
  **Cefotaxime**                    28 (80.0)   7 (20.0)
  **Imipenem**                      2 (5.7)     33 (94.3)

^a^Values are expressed as No. (%).

Of all the isolates, 64% showed resistance to more than three antimicrobial families and identified as multidrug-resistant (MDR). The phenotypic confirmatory test (PCT) confirmed that 35% (n = 35) of isolates were ESBL-producing *Klebsiella* strains.

PCR using universal primers ([Figures 1](#fig28316){ref-type="fig"} and [2](#fig28317){ref-type="fig"}) indicated that among 35 ESBL positive strains, 28 isolates carried *bla*~*CTX-M*~ gene and 9 isolates had *bla*~*PER*~ gene. GenBank accession numbers obtained for the purified PCR products were KJ803828 and KJ803829 respectively.

![Amplification of *bla*~*CTX-M*~Gene Among ESBL Positive *Klebsiella* Strains\
Lane M, 100-bp DNA ladder as the molecular size marker; lanes 1 - 13, *bla*~*CTX-M*~-positive *Klebsiella* isolates; lane 14, negative control; lane 15, positive control.](ircmj-18-03-22260-g001){#fig28316}

![Amplification of *bla*~*PER*~ Gene Among ESBL Positive *Klebsiella* Strains\
Lane M, 100-bp DNA ladder as the molecular size marker; lane 1, negative control; lane 2, positive control; Lane 3, *bla*~*PER*~-negative *Klebsiella* isolate; Lane 4, *bla*~*PER*~-positive *Klebsiella* isolate.](ircmj-18-03-22260-g002){#fig28317}

5. Discussion {#sec149568}
=============

*Klebsiella* spp. is considered as the most common ESBL producing organism ([@A22260R8], [@A22260R27]). ESBL producing *Klebsiella* strains are a major concern for clinical therapeutics; therefore, some supplementary tests are needed to determine ESBL producing bacteria ([@A22260R28]). In the current study, 35% of the *Klebsiella* strains isolates were ESBL producer by PCT test. A frequency of 46.9% ESBL production was reported by Raei et al. ([@A22260R9]) among urinary isolates of *K. pneumoniae* in Tehran. In contrast, lower rates of ESBL production were detected in comparison to other studies in Iran and some parts of Middle East ([@A22260R15], [@A22260R17], [@A22260R18]). The results show that the prevalence rates of ESBL production are different in different countries or different parts of each country ([@A22260R14], [@A22260R15], [@A22260R17]-[@A22260R21]). This could be due to different antibiotic policies in each region.

In accordance with other reports, the resistance rate among ESBL producing *Klebsiella*isolates was higher than that of non-ESBL producing *Klebsiella* isolates ([@A22260R29]-[@A22260R31]).

The current study findings showed a high rate of resistance to the third generation cephalosporins including cefotaxime (%80), ceftazidime (%74.3) and ceftriaxone (%71.4) among ESBL producing *Klebsiella* isolates. In a report from Imam Hussein hospital in Tehran, 95.6%, 89.1% and 96.7% of ESBL producing *K. pneumoniae* isolates were resistant to cefotaxime, ceftazidime and ceftriaxone, respectively ([@A22260R9]). High rates of resistance to third generation cephalosporins in CTX-M producers are also documented from China ([@A22260R29]) and Croatia ([@A22260R30]). These antibiotics are third generation cephalosporins commonly used in Iranian hospitals and resistance genes could be selected easily due to selection pressure.

In the current study, 25.7% of the ESBL producing *Klebsiella* isolates were resistant to ciprofloxacin. This is in contrast with the results documented by Vranic-Ladavac in Croatia showing that all (ESBL)-producing *Klebsiella pneumonia*associated with a nosocomial outbreak were resistant to ciprofloxacin ([@A22260R31]). High rates of resistance to ciprofloxacin in CTX-M producer *Klebsiella* isolates were also reported from Canada and Austria ([@A22260R32], [@A22260R33]). Another finding indicated that rates of resistance to imipenem were 5.7% among ESBL producing *Klebsiella* isolates. In a study in Karaj all *K. pneumoniae* isolates were susceptible to imipenem ([@A22260R34]). Du et al. ([@A22260R29]) reported 3.3% resistance to imipenem among *Klebsiella pneumoniae* isolates. In another study conducted by Edelstein et al. ([@A22260R26]) in Russian hospitals 100% sensitivity to imipenem was reported. Imipenem is the drug of choice for complicated infections caused by ESBL-producing *Klebsiella* strains; therefore, emerging 5.7% resistance to imipenem is alarming.

In the present study a high frequency of MDR was found among *Klebsiella* isolates and all ESBL producing *Klebsiella* isolates were identified as MDR strains. In a study conducted by Raei et al. ([@A22260R9]) multidrug-resistance was observed in 96.7% of ESBL *K. pneumoniae* isolates. Similar findings were reported in other studies ([@A22260R29], [@A22260R35]). This result could be due to the point that plasmids encoding ESBLs also contain resistance genes to other antibiotics.

The global dissemination of *bla*~*CTX-M*~ ESBL genes over the years are described as the CTX-M pandemic; and CTX-M producing *Klebsiella* strains emerged as significant cause of hospital acquired infections ([@A22260R36]). The current study results showed that 28% of *Klebsiella* isolates carried *bla*~*CTX-M*~ type gene. The frequency of *bla*~*CTX-M*~ type gene in *Klebsiella* strains in the present study was lower than that of Russian hospitals ([@A22260R26]), but was in agreement with the results of studies conducted by Nasehi et al. ([@A22260R35]) and Paterson et al. ([@A22260R37]), which reported gene frequencies of 22.5% and 23.3% among *K. pneumonia* isolates respectively.

In the current study of 35 ESBL producer *K. pneumoniae* isolates 80% carried *bla*~*CTX-M*~ gene. Kiratisin et al. ([@A22260R38]) documented a strikingly high prevalence of *bla*~*CTX-M*~ gene (99.2%) among ESBL producing *K. pneumoniae* isolates at two university hospitals in Thailand. The *bla*~*CTX-M*~ genes are the predominant ESBL-related *bla* genes, in most parts of the word and high prevalence of *bla*~*CTX-M*~ gene in this study showed that CTX-M-type ESBL is endemic in the region.

The study identified 9% presence of *bla*~*PER*~ in *Klebsiella* isolates which was in agreement with the reports by Nasehi et al. ([@A22260R35]) and Celenza et al. ([@A22260R39]). In contrast, the prevalence of 55% and no occurrence were reported from Turkey and Italy respectively ([@A22260R35]). Finally, the study found that of the 35 ESBL producing *Klebsiella* isolates 22.9% carried both *bla*~*CTX-M*~ and *bla*~*PER*~ genes. It was reported that MDR *Klebsiella* strains may be associated with several different betalactamases ([@A22260R29]). The coexistence of *bla*~*CTX-M*~ type and *bla*~*PER*~ β-lactamases may have also contributed to the high rate of antimicrobial resistance in these isolates.

In conclusion, the current study result showed high ESBL occurrence with CTX-M type among *Klebsiella* isolates in Shahid-Beheshti hospital in Kashan that could be a major problem to treat *Klebsiella* infections.
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